Načítá se...
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
BACKGROUND: Therapies that maintain remission for patients with Crohn's disease are essential. Stable remission rates have been demonstrated for up to 2 years in adalimumab-treated patients with moderately to severely active Crohn's disease enrolled in the CHARM and ADHERE clinical trials....
Uloženo v:
| Vydáno v: | Aliment Pharmacol Ther |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Blackwell Publishing Ltd
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4670480/ https://ncbi.nlm.nih.gov/pubmed/24134498 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.12499 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|